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Abstract
Background: Enterovirus 71 (EV71) has caused several epidemics of hand, foot and mouth diseases (HFMD) in Asia and now
is being recognized as an important neurotropic virus. Effective medications and prophylactic vaccine against EV71
infection are urgently needed. Based on the success of inactivated poliovirus vaccine, a prototype chemically inactivated
EV71 vaccine candidate has been developed and currently in human phase 1 clinical trial.
Principal Finding: In this report, we present the development of a serum-free cell-based EV71 vaccine. The optimization at
each step of the manufacturing process was investigated, characterized and quantified. In the up-stream process
development, different commercially available cell culture media either containing serum or serum-free was screened for
cell growth and virus yield using the roller-bottle technology. VP-SFM serum-free medium was selected based on the Vero
cell growth profile and EV71 virus production. After the up-stream processes (virus harvest, diafiltration and concentration),
a combination of gel-filtration liquid chromatography and/or sucrose-gradient ultracentrifugation down-stream purification
processes were investigated at a pilot scale of 40 liters each. Although the combination of chromatography and sucrose-
gradient ultracentrifugation produced extremely pure EV71 infectious virus particles, the overall yield of vaccine was 7–10%
as determined by a VP2-based quantitative ELISA. Using chromatography as the downstream purification, the virus yield
was 30–43%. To retain the integrity of virus neutralization epitopes and the stability of the vaccine product, the best virus
inactivation was found to be 0.025% formalin-treatment at 37uC for 3 to 6 days. Furthermore, the formalin-inactivated virion
vaccine candidate was found to be stable for .18 months at 4uC and a microgram of viral proteins formulated with alum
adjuvant could induce strong virus-neutralizing antibody responses in mice, rats, rabbits, and non-human primates.
Conclusion: These results provide valuable information supporting the current cell-based serum-free EV71 vaccine
candidate going into human Phase I clinical trials.
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Introduction
Enterovirus 71 (EV71) infections have recently emerged in Asia
as a serious cause of hand, foot and mouth disease (HFMD) in
children that can lead to severe neurological complications and
death [1–4]. Different types of vaccines against EV71 infection are
being developed [4–6] and promising candidates are being
evaluated in human Phase 1 clinical trials [6]. EV71 is a non-
enveloped RNA virus of the family Picornaviridae, first identified in
1969 in the United States [7]. The EV71 virus particle contains a
single molecule of plus sense ssRNA (7.5–8.5 kb). The complete
nucleotide sequence of the EV71 prototype strain BrCr has been
determined and contains four structural proteins: VP1, VP2, VP3
and VP4 [8,9]. The cleavage of VP0 into VP2 and VP4 has been
shown as a key capsid maturation step and also is important to
viral RNA encapsidation [8,10]. Two structural proteins VP1 and
VP4 have been used for molecular epidemiological investigation
and EV71 genotyping. Based on these studies, EV71 is currently
classified into 3 genotypes, A, B and C and genotypes B and C are
further divided into B1–B5 and C1–C5 sub-genotypes [11,12].
Recent epidemics in Malaysia, Singapore, Taiwan, and Thailand
were caused by B5 isolates; the virus strain that circulated in
mainland China was C4 [12,13]. Therefore, an effective EV71
vaccine should elicit strong cross-neutralizing antibody responses
against different genotypes of EV71 in young children. Two
different membrane proteins, human P-selectin glycoprotein
ligand-1 (PSGL-1) [14] and human scavenger receptor class B,
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34834member 2 (SCARB2) [15] have been identified as cellular
receptors for EV71. Transgenic mice carrying these genes are
being engineered and should be useful for HFMD vaccine
development.
The heat-inactivated EV71 virion produced from Vero cell
grown in serum-containing culture media has been shown to elicit
more effective immune responses than those obtained from the
recombinant VP1 protein or DNA vector vaccines in mice [4–
6,16–18]. In the present study, we describe a scalable and reliable
manufacturing process for a chemically-inactivated EV71 vaccine
candidate that was capable of eliciting cross-neutralizing antibody
responses in different animal immunogenicity studies. Our present
findings provide valuable information for a serum-free, cell-based,
heat-inactivated EV71 vaccine candidate going for human phase I
clinical trials.
Materials and Methods
Ethics Statement
All experiments were conducted in accordance with NHRI
Laboratory Animal Center guidelines, and approved by the NHRI
Institutional Animal Care and Use Committee (Approval No. N-
HRI-IACUC-098033-A & NHRI-IACUC-099053-A).
Animal welfare and steps taken to ameliorate suffering
There were five well-trained veterinarians in Animal Health
Research Institute of Taiwan (AHRI) to take care of total 15
monkeys. Monkey immunogenicity study was performed accord-
ing to study protocol NHRI-IACUC-099053-A. All juvenile
monkeys (macaques) were kept in a secured specific pathogens
free (SPF) room with locked double-doors and security camera to
ensure no animal escape or irrelevant person entry. Individual
monkey was housing in a double-door, squeeze-back cage
(62662672 cm), with toys to enrich the environment. Monkeys
can contact each other in vision but not physical. Monkeys were
fed with fresh local fruits twice a day. Monkeys received the
routine check up (X-ray, stool exam, and serological tests). The
related record (critical blood chemistry (CBC) data, feeding
record, and body weight) would be kept for 10 years. All monkeys
were chemically restrained with Zoletil (1.4–4.5 mg/Kg) before
immunization or bleeding. The vital sign was monitored by breath
and heart beating. In addition, animal would be euthanasia and
removed from the study if one of the following signs appears: (1)
unable to eat or drink; (2) unable to relieve a severe pain even
receiving a medical treatment by a certificated veterinarian; (3) a
high-risk pathogen infection. Normally monkeys were immunized
intramuscularly (leg) with the alum-adsorbed inactivated EV71
vaccine candidate; and they were boosted twice with the same
dose three weeks interval after priming. Immunized monkeys were
bled three weeks after the final boost, and 10 mL of blood was
collected for detecting specific IgG antibody titer and neutralizing
antibody titer. After blood samples collections, monkeys were
placed back into original cages for recovery. Usually, 15,20 min-
utes was needed and veterinarian monitored them. If an animal
appeared to be in poor condition, an adequate medical treatment
or environment improvement would be used to relieve the pain or
distress. If the condition of an animal is out of control or is
moribund, it may be euthanized by Pentobarbital (100 mg/Kg; iv
injection) after a certificated veterinarian’s review. After the study
was completed, monkeys were still kept in AHRI with the same
housing conditions. The health condition of monkeys will be
checked every 3–6 months with CBC examination and body
weight.
Cells and virus
Master and working Vero cell and virus (E59 strain) seed banks
were established following cGMP guidelines, characterized to
fulfill the requirements for the manufacture of biological products
by BioReliance (UK), and reported in our previous study [19].
Medium selection in 75 cm
2 T-flasks
The serum-containing (SC) medium contained basal medium
DMEM purchased from Invitrogen (UK) and 5% fetal bovine
serum (FBS) purchased from Moregate Biotech (Australia). Plus
Vero and HyQ medium were purchased from Cesco Bioengi-
neering Co. (Taiwan) and Hyclone (USA), respectively. VP-SFM
and ExCell were supplied by Invitrogen (UK), and supplemented
with 4 mM L-glutamine before use. Each 75 cm
2 T-flask was
inoculated with approximately 1.0610
6 cells and grown for 3 days
in 20 mL medium. Every 24 hours, cell counts were determined
by detaching cells in each T-flask using 4 mL of Trypsin-EDTA
solution purchased from Invitrogen (UK). At each time point, cell
counts were performed in triplicate.
Pilot Scale purification of EV71 virus using liquid
chromatography
EV71 virus stock was produced using the roller bottle
technology, and purified by an AKTA Pilot liquid chromatogra-
phy system purchased from GE Healthcare (USA) equipped with
Sepharose Fast Flow 6 gel, and reported in our previous studies
[10,19].
SDS-PAGE analysis and Western blotting
SDS-PAGE and Western blot analyses of the purified EV71
vaccine bulk were carried out according to previously-reported
protocols [10].
Animal immunogenicity studies
Mouse immunogenicity studies were conducted according to
previously-reported protocols [10]. In parallel, rabbits, macaque
monkeys and rats were immunized IM with 5–20 mg of protein
formulated with 1.5 mg of alum per dose. Sera were collected two
weeks after each immunization and used for immunological
analysis.
Virus neutralizing assay
Virus neutralization titer of each sample was determined using
TCID50 assay according to the previously-reported protocols
[10,20].
Enzyme-Linked Immunosorbent Assay (ELISA)
The VP2 epitope-specific quantitative ELISA was carried out
according to previously-reported protocols [21]. The reactivity of
the antibody to synthetic peptide VP1–43 [22] was analyzed by
peptide-ELISA according to the protocol previously reported by
Panezutti et al. [23].
Stability profiles of EV71 vaccine
Eighty vials (3 mL each) containing either vaccine bulks
(formalin-inactivated EV71 virion) or vaccine products (20 mgo f
protein of vaccine bulk formulated with 3 mg of aluminum
phosphate in 1 mL of PBS) were stored at 4 or 25uC for stability
studies. The stability of vaccine bulk was evaluated every 2 weeks
for the first month and then every 3 months for up to 1 year using
BCA protein assay, VP2 Q-ELISA, SDS-PAGE and Western blot
analysis, and mouse immunogenicity study. The stability of the
vaccine product was measured every month for the first 3 months
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(to analyze the unabsorbed protein), sterility tests and mouse
immunogenicity studies.
Residual DNA detection
Residual cellular DNA was detected by the ThresholdH System
(Model 0200–0500) using the Total DNA Assay Kit (MDC-
R9004), both purchased from Molecular Devices Co. (USA). Five
hundred mL aliquots of Zero Calibrator, Positive Control, High
Calibrator from the Total DNA Assay Kit and the diluted samples
(DNA content ,400 pg/mL) were added into sterile DNA-free
tubes. The double-stranded DNA in the tubes was denatured by
heating at 105uC for 15 minutes, and the tubes were kept on ice
until use. The standard solutions of single-stranded DNA into 0,
3.1, 6.3, 12.5, 25, 50, 100 and 200 pg per 0.5 mL were prepared
using the High Calibrator. Labeling Reagent from the Total DNA
Assay Kit was mixed with DNA samples and standards, and the
mixtures were incubated at 37uC for 60 minutes. The filter block
was pre-washed with the freshly-prepared substrate solution
according to manufacturer instructions. Each assay mixture was
transferred to the filter block, then filtered and washed. The
concentration of DNA in the filter block was measured by
ThresholdH System and calculated using the included ThresholdH
software.
Residual cellular protein detection
Vero cell protein-specific ELISA was used to measure the
residual host protein content remained in EV71 vaccine samples.
The in-house standard of Vero cell lysate was prepared from Vero
cells grown in 200 mL SF medium in a roller bottle. The Vero
cells were harvested and frozen at 280uC overnight. The cells
were frozen and thawed several times to generate cell lysate
standard. The total protein concentration of Vero cell lysate
standard was determined by BCA protein assay. One hundred
micrograms of Vero cell lysate was mixed with the complete
Freund’s adjuvant (CFA) and used to immunize rabbits 3 times for
hyper-immune anti-Vero cell protein sera production. The quality
and titer of rabbit anti-Vero cell protein sera were analyzed using
Western blot. The Vero cell lysate standard was diluted into
0.15265, 0.3125, 0.625, 1.25, 2.5, 5 and 10 mg of protein/mL to
generate the standard curve. One hundred mL of the diluted
samples in the coating buffer were transferred into a 96-well
microplate and tests were performed in duplicate. The microplate
was sealed and incubated overnight at room temperature, washed
with 0.05% Tween-20 in phosphate buffer saline (PBS), then
blocked with 1% bovine serum albumin (BSA) in PBS at room
temperature for 2 hours. Purified rabbit anti-Vero cell lysate IgG
as prepared above was 1:1000 diluted in 1% BSA/PBS, then
added into each well and incubated at room temperature for
2 hours. The microplate was washed 3 times with 0.05% Tween-
20 in PBS, a 1:5000 dilution of goat anti-rabbit IgG conjugated to
peroxidase (Chemicon USA) was added and incubated for 1 hour
at room temperature. After PBS, the microplate was washed again
6 times with 1% BSA/PBS, then peroxidase substrate (KPL USA)
was added and kept in the dark for 30 minutes. The stop solution
(2N H2SO4) was added into the microplate, and the absorbance of
each well was read at 450 nm by a microplate reader (Thermo
Multiskan Spectrum USA) according to manufacturer instructions.
Results and Discussion
Evaluation and selection of serum-free medium
The performance of different media for Vero cell growth was
screened and evaluated through the direct adaptation method
[10,17,24]. The selection criteria were based on consistent cell
growth performance over several passages. The cells were cultured
in four different commercially-available SF media (Plus Vero, VP-
SFM, HyQ and ExCell) and one SC medium (DMEM with 5%
FBS supplement) in 75 cm
2 flasks over three passages after
inoculation. As shown in Figure 1, the average cell counts in the
SC medium, VP-SFM and Plus Vero were found to be higher than
those found in the Excell and HyQ SF media (p,0.05). We further
examined the consistency of VP-SFM and Plus Vero SF media for
Vero cell growth, and found three batches of VP-SFM to have
similar levels in cell growth profile, whereas the culture in Plus
Vero showed greater fluctuations and sometimes lower cell growth
rates (data not shown).The current results suggested that the VP-
SFM could consistently promote the cell growth and virus yield
(see below). Thus, the VP-SFM was selected as the SF medium
and was subsequently used in all later experiments.
Optimization of EV71 virus yield
To evaluate the efficiency of E59/EV71 virus production in
Vero cells grown in the VP-SFM medium, virus growth profile in
T-flasks were done at four different multiplicities of infection
(MOI): 0.01, 0.001, 0.0001 and 0.00001. As shown in Figure 2A,
the virus titers in general decreased slightly during the first 2 days
and then increased steadily after inoculation. The highest virus
titer was 2610
7 TCID50/mL at 4 and 7 days post infection (DPI)
for 0.01 and 0.00001 MOI, respectively. We also observed that
increasing Vero cells (2–2.5610
6 cells) inoculation at the
beginning of cell culture could generate a better virus yield
(Figure 2A). To test whether temperature could influence virus
growth and yield, the E59 strain was grown at various
temperatures from 32 to 37uC. No significant differences in virus
growth profile or yield were observed (data not shown). Therefore,
0.00001 MOI and 37uC were selected and subsequently used in all
later production runs.
Pilot scale up-stream process development
The virus growth profiles of three typical pilot scale production
batches (2006200 mL roller bottles in each run) are shown in
Figure 2B. In contrast to the results obtained from T-flasks, the
virus titer was capable of reaching 10
7 TCID50/mL at 3 DPI. The
production kinetics of the E59 strain was similar when using
200 mL or 400 mL of culture medium (data not shown). EV71
virus was harvested and collected from the culture supernatant of
each bottle at 5 DPI, prior to the onset of cytopathic effects. The
potential cell debris was then removed by micro-filtration through
a 0.65 mm membrane. To monitor and optimize the up-stream
process, culture supernatants collected from each manufacturing
run were assayed for their titers of infectious virus particles using
the TCID50 assay and VP2 epitope contents by Q-ELISA as
previously described [21]. The titers of infectious virus particles in
the supernatants harvested from three cGMP lots were found to be
11.70, 6.31, and 10.5610
6 TCID50 units per mL for Lot #1, 2,
and 3, respectively (Table 1). VP2 epitope contents were measured
by Q-ELISA and found to be 11.9, 7.73, and 8.1 units of VP2 per
mL in Lot #1, 2, and 3, respectively. The VP2 epitope contents
were at least 3 folds higher than those obtained from virus
produced in serum-containing medium [19]. The reason is unclear
to us at this moment.
The VP2 epitope content per 10
6 TCID50 infective units were
calculated to be 1.02 (11.9/11.7), 1.23 (7.73/6.31), and 0.77(8.1/
10.5) for Lot #1, 2, and 3, respectively. These results are
consistent with our previous small-scale research studies [21] that
have shown the VP2 epitope content and the titer of infectious
viral particles to be uncorrelated. In contrast, the ratio between
Cell-Based EV71 Vaccine Candidate
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e34834Figure 1. The growth profiles of Vero cell grown in serum-contain medium (SC) and different serum-free media (SF). Vero cells (2610
5
cell/ml) was cultured in 75T-flask and counted for viable cell number every 24 hours (0, 24, 48, 72, 96, 120 and 144 hours). The conditions for cell
culture were described in the Materials and Methods section.
doi:10.1371/journal.pone.0034834.g001
Figure 2. The optimization of the up-stream process for EV71 virus production. (A) The T-flask was seeded with either 1.0,1.5610
6 or
2.0,2.5610
6 Vero cells, then after 2–3 days the cells were infected by the different ratio of E59/EV71 virus. The effects of different M.O.I were
detected in the kinetic profile of virus produced from Vero cell grown in the VP-SFM medium. (B) The consistency of 3 Lots of EV71 virus production
in the roller bottles. Virus titer was detected every day by TCID50 for 5 days.
doi:10.1371/journal.pone.0034834.g002
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found to be relatively consistent in all three Lots (0.008, 0.006, and
0.006 for Lot #1, 2, and 3, respectively). Together, both results
suggest that EV71 viral antigens are consistently produced from
Vero cells grown in the VP-SFM culture system, but varying
amounts of viral antigens are assembled to become infectious virus
particles.
To facilitate downstream purification, the crude virus bulk was
concentrated 20- to 40-fold using a 100 kDa cut-off diafiltration
membrane in a tangential flow filter (TFF) cassette. As shown in
Table 1, the TFF process was found to be efficient with high
recoveries of viral antigens based on Q-ELISA units of VP2
(119%, 97%, and 104% for Lot #1, 2, and 3, respectively). The
TFF process not only concentrated the viral antigens, but also
removed significant amounts of cell proteins as the ratio between
VP2 content and total protein as shown in Table 1 increased .40
fold (0.25/0.006 for Lot #3). However, Q-ELISA units of VP2
epitope per 10
6 TCID50 infectious units were found to be 13.6
(531/38.9), 2.8 (249/87.1), and 1.5 (338/223) for Lots #1, 2, and
3, respectively. Again, the VP2 epitope content measured by Q-
ELISA did not correlate well with TCID50 values. These results
suggest that the un-assembled VP2 antigens were not removed
from the virus concentrate at the 100 kDa TFF step. These results
may also explain why 300 kDa cut-off diafiltration membranes
used in the TFF step were less effective in the recovery of VP2
content as determined by Q-ELISA.
Pilot scale downstream purification process
Three pilot-scale virus concentrates (,1 liter) were purified
using the AKTA Pilot liquid chromatography system (Table 1).
The EV71 virus was generally identified and located in fractions 3
to 8 as determined by SDS-PAGE, Western blot, and TCID50.
The EV71 virus fractions were pooled and concentrated using a
100 kDa TFF membrane. As shown in Table 1, ELISA units of
VP2 epitope per 10
6 TCID50 infectious units were found to be
4.87 (181.3/37.2), 4.15 (130.4/31.4), and 2.05 (214.4/104.7) for
Lot #1, 2, and 3, respectively. These results suggest that the virus
bulk pooled from multiple fractions may still contain various
amounts of defective and infectious EV71 particles. As shown in
Table 1, the ELISA units of VP2 epitope per mg of protein was
found to be 2.43, 2.02, and 3.46 for Lots #1, 2, and 3,
respectively. These results are close to those obtained from the 3
previously reported research Lots (3.8, 5.3 and 3.4) [21].
Furthermore, the overall recovery yield based on VP2 content
determined by ELISA varied (27.9, 37.1, and 57.0% for Lots #1,
2, and 3, respectively) in these three pilot runs. The gel-filtration
chromatography removed .95% (.1300 decreased to 62 mg/mL
of total protein for Lot #3) of potential contaminants. The residual
host cell proteins within the virus bulks was determined using Vero
cell-specific ELISA as described in the Materials and Methods and
found to be 2.72, 2.61, and 2.38 mg/mL for Lots #1, 2, and 3,
respectively. The current results indicate that 5% (2.61/50.3 of
Lot #2) of total protein are residual Vero cell proteins within the
virus bulks. As a result, there is still room for improvement in the
chromatographic purification process.
Two hundred mL of formalin-inactivated chromatographically-
purified viral stock (64 mg/mL) was further purified using sucrose
gradient ultracentrifugation as previously described [10]. Two
kinds of EV71 virus particles were detected by TCID50 assay and
Western blot analysis, the defective and infective particles were
found in the fractions containing 25–28% and 35–38% sucrose,
respectively (data not shown). When protein concentrations of
both EV71 particle pooled fractions were measured by BCA
method, it was found that there were 3 times more defective
Table 1. Summary of in-process characterizations of EV71 vaccine bulk produced from serum-free medium.
Lot # Process step Total volume (L)
TCID50
a (610
6/
mL)
Total Protein
b
(mg/mL)
VP2 epitope
c
(Unit/mL) Recovery
d (%)
VP2 epitope/
Total Protein
(Unit/mg)
Lot #1 Harvest 41.0 11.7 1459.8+/25.5 11.9+/20.8 100 0.008
Dif/Con
e 1.10 38.9 825.6+/29.5 531.0+/214.5 119.7 0.64
LC
f 0.75 37.2 74.5+/20.8 181.3+/216.7 27.9 2.43
Formalin
inactivated
0.75 53.0+/21.5 198.4+/221.3 30.5 3.74
Lot #2 Harvest 40.0 6.31 1373.1+/229.1 7.73+/20.23 100 0.006
Dif/Con 1.20 87.1 1351.7+/213.6 249.0+/212.47 96.6 0.18
LC 0.88 31.4 64.4+/20.89 130.4+/29.07 37.1 2.02
Formalin
inactivated
0.80 50.3+/21.27 130.4+/26.7 33.9 2.59
Lot #3 Harvest 40.7 10.5 1318.7+/227.6 8.1+/20.31 100 0.006
Dif/Con 1.00 223.9 1333.4+/232.3 338+/217.5 103.9 0.25
LC 0.88 104.7 62.0+/20.74 214.4+/225.1 57.0 3.46
Formalin
inactivated
0.85 60.7+/22.82 167.0+/27.43 43.1 2.75
ND: not determined.
aTCID50 is the median tissue culture infective dose of EV71 that produces pathological cytopathic effects (CPE) in 50% of inoculated cell cultures.
bTotal protein concentration was determined by the BCA protein assay.
cVP2-specific epitope content was determined by Q-ELISA [19].
dRecovery was calculated using the total VP2 epitope content at each step divided by the total VP2 epitope at the harvest stage.
ediafiltration/concentration step.
fgel-filtration chromatography purification.
doi:10.1371/journal.pone.0034834.t001
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our previous report [10], the purified infectious EV71 virus was
shown to be consisted of all 4 structural proteins VP1, VP2, VP3
and VP4. In contrast, in the defective viral particles VP0, VP1 and
VP3 protein bands were found to be the major components as
shown in the SDS-PAGE and Western blot analysis [10].
Although ultra-pure EV71 virus bulk could be obtained by
combining the purification process of liquid chromatography with
sucrose gradient ultracentrifugation, the recovery yield was less
than 20% of the chromatographically-purified viral stock. Since
the defective particle fractions are also immunogenic and could
elicit neutralizing antibody responses in both immunized mice and
rabbits as previously reported [10,19,21], it was therefore decided
that the pilot-scale downstream purification would use gel-
filtration chromatography.
Chemical inactivation optimization
In previous reports [10,19,21,22,25], the purified EV71 virus
bulk could be inactivated with formalin either at 4uC for weeks or
Figure 3. The temperature effect in the kinetic of formalin-inactivation of EV71 virus. Purified E59/EV71 was inactivated by 0.025% (v/v)
formalin at different temperature and the residual of virus infectivity was detected by plaque assay performed triplicate at different time points.
doi:10.1371/journal.pone.0034834.g003
Figure 4. The stability profiles of different Lots of EV71 vaccine products stored at 46C for various time and analyzed by SDS-PAGE
(Panel A) and Western blot (Panel B & C). Lane M is MW Markers; lane 1 is EV71 vaccine product produced from serum-containing medium and
stored at 4uC for 26 months; lanes 2 and 3 are EV71 vaccine products derived from Lot #1 and 2 and stored at 4uC for 13 and 4 months, respectively.
Monoclonal antibody used in the Panels B and C are MAB979 specific for VP2 and N16 specific for VP1, respectively.
doi:10.1371/journal.pone.0034834.g004
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validated for virus reversion. Therefore, the formalin-inactivation
kinetic was performed at 4, 25, and 37uC. The results are shown in
Figure 3, no infectivity was detected in the samples taken 18 and
72 hours after exposure to 0.025% (v/v) of formalin at 37 and
25uC, respectively. After 24 days, no infectious EV71 was
observed in the samples taken from 4uC. Based on the current
inactivation kinetic, the complete viral inactivation for 10
12
TCID50 titer virus bulk would require 2.16, 12.6 and 31.64 days
at 37, 25, and 4uC, respectively (Figure 3). After 0.22 mm sterile
filtration, the total protein concentration measured by the BCA
assay was found to have 20–30% loss of protein content during the
inactivation and sterile filtration steps (Table 1). However, the Q-
ELISA unit in the vaccine bulk was found to be similar to the value
observed in the virus bulk before inactivation. These results
suggest that formalin inactivation did not modify the VP2 epitope
content as determined by VP2 Q-ELISA. In addition, the residual
DNA in the EV71 vaccine bulk was determined according to the
protocol described in the Materials and Methods section and
found to be 16.67, 8.13, and 2.87 pg/mL for Lot #1, 2, and 3,
respectively. These levels would pass the acceptance criteria for
human vaccine (10 ng/dose) based on FDA guidelines.
Immunogenicity studies of EV71 vaccine candidates
The quality of EV71 vaccine bulks (formalin-inactivated EV71
whole virions) was analyzed by SDS-PAGE and Western blots
(Figure 4). After silver-staining SDS-PAGE gels, the dominant
protein bands with molecular weight (MW) 28 and 38 kDa were
observed in the vaccine bulks (Figure 4A, lanes 2 & 3). From our
previous studies [10,19,21,22,25], protein bands with MW 38 and
28 kDa correspond to VP0/VP1 and VP2, respectively. Since the
gel was loaded with the same amount of vaccine bulk based on
protein concentration (2 mg per lane), it was suggested that Lot #1
contained more VP0/VP1 and VP2 antigens than Lot #2. This
observation is consistent with the ratio of VP2 epitope/total
protein found in Lots #1 (3.74) and #2 (2.59). The vaccine bulks
were further analyzed by Western blot using two monoclonal
antibodies (MAb) with different specificity: MAB979 recognizes an
Table 2. Immunogenicity studies of EV71 vaccine bulks.
Animal Model Vaccine Lot #
Total proteins
(mg/dose)
VP2 Q-ELISA
unit/dose IgG Titer (GMT) TCID50 Neutralization titer (GMT)
B4/E59 B4/S0302 C4 B5
BALB/c Mouse 1 2 7.5 4,525 443 256 32 128
2 2 5.2 2,934 233 ND* 64 256
3 2 5.5 2,851 234 ND ND ND
Rat 2 10 26 12,800 654 ND 64 128
Rabbit-G1 1 5 18.8 .32,000 13,573 5,677 8,192 5,677
Rabbit-G2 1 10 37.6 .32,000 13,318 ND 13,520 16,384
Rabbit-G3 2 5 13 .32,000 17,093 ND ND ND
Rabbit-G4 2 10 26 .32,000 19,308 ND ND ND
Macaque 1 10 37.6 .32,000 5,623 ND 5,623 3,169
Macaque 3 5 13.8 25,600 3,169 ND ND ND
Macaque 3 10 27.6 25,600 8,912 ND ND ND
Eight mice per group and 5 rats per group were immunized twice with formalin-inactivated EV71 virion formulated with alum. Two rabbits per group and individual
macaques were immunized three times with formalin-inactivated EV71 virion formulated with alum. The immunization protocol, IgG tier and virus neutralization assay
are described in the Materials and Methods section.
*not done.
doi:10.1371/journal.pone.0034834.t002
Table 3. Stability profiles of EV71 vaccine bulks.
Vaccine Bulk Lot #1 stored at different temperature Vaccine bulk Lot #3 stored at different temperature
Time Total protein (mcg/mL) VP2 epitope (Unit/mL) Total protein (mcg/mL) VP2 epitope (Unit/mL)
46C2 5 6C4 6C2 5 6C4 6C2 5 6C4 6C2 5 6C
Initial 57.01 57.01 198.35 227.54 48.76 48.76 199.80 199.80
2 weeks ND 60.73 ND 181.65 ND 50.86 ND 209.55
1 month 58.75 58.25 198.29 150.59 47.74 48.46 206.02 191.36
3 month 58.55 60.50 168.69 156.76 52.59 51.31 192.48 170.48
6 month 57.70 59.27 188.05 137.49 52.19 53.76 190.29 168.52
9 month 58.75 ND 180.35 ND 51.54 51.07 218.64 145.36
12 month 47.76 ND 174.03 ND 46.18 ND 214.39 ND
The total protein and VP2 antigen content in the vaccine bulks were determined by BCA method and VP2 Q-ELISA, respectively.
doi:10.1371/journal.pone.0034834.t003
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Figures 4B and C, both MAb recognized similar antigen patterns
in both Lots #1 and 2. We observed similar Western blot results
from Lot #3 (data not shown). These results indicate that the
antigen patterns of EV71 vaccine bulks were produced consistently
throughout the current manufacturing process.
Mouse immunogenicity studies summarized in Table 2 revealed
that the formalin-inactivated EV71 virions were highly potent in
eliciting virus neutralization titer that were correlated with VP2
epitope units [10,19,21,22,25]. Although the neutralization titer
was decreased (2- to 14-fold), sera from mice immunized twice
with EV71 vaccine bulk were capable of cross-neutralizing other
isolates from B4, B5 sub-genotype and C4 genotype (Table 2).
The results of other animal (rats, rabbits and macaques)
immunogenicity studies are shown in Table 2. Sera from the
immunized animals were found to have strong cross-neutralization
titer against other B subgenotypes and C genotypes of EV71. Our
current results are consistent with the conclusions reported by both
Bek et al. and Dong et al., [26,27]. They had produced formalin-
inactivated EV71 vaccine candidates based on C4 genotype virus
that could elicit cross-genotypes neutralizing antibody responses in
mouse and non-human primate models [26,27]. They suggest that
the common neutralization epitopes of EV71 virus are most likely
conformational that could elicit strong cross-neutralizing antibody
responses against different EV71 genotypes.
Stability profiles of vaccine bulks and formulated vaccine
candidates
The stability profile of 2 different lots of EV71 vaccine bulks based
on protein assay and VP2 Q-ELISA are summarized in Table 3. After
1 year of storage at either 4 or 25uC, there was no sign of protein loss
in the vaccine bulk. VP2 epitope in both vaccine bulk lots remained
relativelystable at 4uC,but there wastrend of epitope lossafter1 and 3
months at 25uC storage for Lot #1 and 3, respectively. Based on
Western blot analyses using two different monoclonal antibodies
N16 specific for the N-terminal peptide of VP1 and MAB979
specific for VP2 shown in Figure 4B and C, there was no EV71
VP1- or VP2-specific protein degradation (no protein fragments
with MW below either VP1 and/or VP2 were observed) in the
vaccine bulks Lot #1 and 3 stored at 4uC for 12 months. Mouse
immunogenicity studies with both vaccine bulks stored at 4uC for 0,
1, 2 and 3 months (262 mg/dose immunization at 2 weeks apart)
revealed that these samples were highly immunogenic and elicited
similar geometric mean titer (GMT) of virus neutralization against
E59 vaccine strain ranging from 200 to 600 (data not shown). No
contamination was observed in all sterility tests. Together, these
stability profiles indicate that the EV71 vaccine bulks produced
from the current manufacturing process stored at 4uC for 1 year are
sterile, stable, and immunogenic in mice.
The vaccine products were analyzed using a Hitachi H-7650
electron microscope according to previously reported protocols
[10], some free inactivated EV71 particles were observed and not
absorbed onto the alum (data not shown). When the kinetics of
vaccine absorption to alum were examined, .50% of protein in the
EV71 vaccine product was absorbed within 1 hour after mixing the
vaccine bulk with the aluminum phosphate at room temperature.
The current data from 3 and 6 months storage also confirm that the
rateofalum absorption is more efficientat25uC inboth Lot#1a n d
3 (Table 4). In addition, it seems that the virus neutralization titers
elicited in mice immunized with the EV71 vaccine product were
correlated with the percentage of protein absorbed to alum,
particularly in Lot #3 (913 vs. 400 at 4uC and 850 vs. 335 at
25uC). The stability profile of the EV71 vaccine product is
supported by no obvious losses of IgG and virus neutralization
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PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e34834titers in mouse immunogenicity studies. In the current 18-month
stability program, the mouse immune responses also reveal that the
EV71 vaccine products from both lots are highly stable for long
term storage at 4uC. Finally, no contamination was observed in
sterility tests performed at 0, 3, 12 and 18 months.
Conclusion
Based the current results, the pilot scale manufacturing process
of cell-based EV71 vaccine has been successfully developed,
optimized, characterized, and quantified. In the up-stream process
development, VP-SFM serum-free medium was identified to be
the optimal medium for Vero cell growth and EV71 virus
production. Gel filtration chromatography was found to be the
most cost-effective for downstream purification, resulting in overall
virus yields as high as 57% (Table 1). The formalin-inactivated
virion vaccine candidate was found to be stable .18 months at
4uC. At microgram-levels, viral proteins formulated with alum
adjuvant could induce strong virus-neutralizing antibody responses
in mice, rats, rabbits, and non-human primates. These results
provide valuable information supporting the current EV71 vaccine
candidate going into human Phase 1 clinical trials.
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